Survival of aggressive variants of papillary thyroid carcinoma in patients under 55 years old: a SEER population-based retrospective analysis

Feng, Jianhua; Shen, Fei; Cai, Wei; Gan, Xiao‐Xiong; Deng, Xiaofang; Xu, Bo

doi:10.1007/s12020-018-1644-y

Cited by 24 publications

(22 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with previously reported studies, patients were mainly women (10)(11)(12)(13)(14)(15)(16)(17)(18)19) and mean age was under 30s (range 10-65 years) (11,12,(16)(17)(18)(19)(20)(21).…”

Section: Discussion/conclusionsupporting

confidence: 91%

Diffuse sclerosing variant of papillary thyroid carcinoma: outcomes of 33 cases

Cavaco¹,

Martins

Cabrera³

et al. 2022

European Thyroid Journal

View full text Add to dashboard Cite

Introduction: Diffuse sclerosing variant of PTC (DSV-PTC) is an uncommon subtype of thyroid cancer. Although an aggressive behavior is often recognized, prognostic significance is still under debate. Objectives: To describe the clinicopathological features and outcomes of a series of DSV-PTC patients. Methods: Retrospective data collection regarding 33 patients diagnosed with DSV-PTC followed at the Endocrine Department of the Portuguese Institute of Oncology in Lisbon between 1981 and 2020. Results: 26 patients (78.8%) were females with a mean age at presentation of 29.4±11.7 years-old. Mean time of follow-up was 19.5±10.6 years (range 0.5 to 39). Histologically, bilateral tumors were present in 72.7% patients (n=24), thyroid capsular invasion was documented in 57.6% (n=19), 45.4% (n=15) had extrathyroidal extension (ETE), and 42.4% (n=14) had lymphovascular invasion. Most patients were staged pT3 (42.4%, n=14) and pN1 (81.8%, n=27). Median lymph nodes resected were 16. None of the patients showed distant metastases at presentation. All patients were treated at least once with 131I. During follow-up, 4 patients (14.8%), with persistent neck disease, were diagnosed with distant metastases, all of them in the lung. Two patients (1.8%) presented recurrent disease in the neck after being considered with no evidence of disease. At the last appointment, 18 patients (54.5%) were in remission, 4 (12.1%) had biochemical evidence of disease, 6 had structural disease, and for 5 patients disease status was considered as undetermined. There was no disease related mortality. Discussion/Conclusion: Our study confirms that DSV-PTC is diagnosed more often in young patients and exhibits a local extensive disease at presentation. On the other hand, even in the presence of distant metastases, no patient died during follow-up.

show abstract

Section: Discussion/conclusionsupporting

confidence: 91%

Diffuse sclerosing variant of papillary thyroid carcinoma: outcomes of 33 cases

Cavaco¹,

Martins

Cabrera³

et al. 2022

European Thyroid Journal

View full text Add to dashboard Cite

show abstract

“…Feng et al also found that not receiving surgery was a risk factor for PTC-specific mortality among patients younger than 55 years. Surgery might therefore be appropriate for PTC patients regardless of age [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

“…The SEER data set was initiated in 1973 as the main USA population-based cancer registry. This database contains data from many geographic regions and covers information on demographics, staging, treatments, and survival; however, certain specific clinical details are not available [ 13 ].…”

Section: Methodsmentioning

confidence: 99%

Competing-Risks Model for Predicting the Postoperative Prognosis of Patients with Papillary Thyroid Adenocarcinoma Based on The Surveillance, Epidemiology, and End Results (SEER) Database

Bian¹,

Han

et al. 2020

Med Sci Monit

View full text Add to dashboard Cite

Background The aim of this study was to identify accurate prognostic factors for postoperative papillary thyroid adenocarcinoma (PTAC) using a competing-risks model based on data from the Surveillance, Epidemiology, and End Results (SEER) database. Material/Methods Data on patients with PTAC who had received surgery between 2010 and 2015 in the SEER database were extracted. A univariate analysis was performed while considering competing risks using the cumulative incidence function, with Nelson-Aalen cumulative risk curves of the incidence function for PTAC-specific death were calculated and then compared between 2 groups using Gray’s test. To identify the factors that affect the cumulative incidence of PTAC-specific death, a multivariate analysis using the Fine-Gray model was performed. Results The 8324 eligible surgical PTAC patients included 101 patients who died from PTAC and 129 patients who died from other causes. The univariate Gray’s test revealed that the cumulative incidence rate for events of interest was significantly affected ( P <0.05) by age, sex, marital status, metastasis, differentiation grade, American Joint Committee on Cancer (AJCC) stage, radiation status, chemotherapy status, regional lymph nodes removal, and tumor size. Multivariate competing-risks analyses showed that age, sex, metastasis, differentiation grade, radiation status, chemotherapy status, and tumor size were independent risk factors for the postoperative prognosis of PTAC patients ( P <0.05). The results of multivariate Cox regression were different, with marital status also appearing as an independent risk factor. Conclusions This study established a competing-risks analysis model to evaluate the risk factors of surgical PTAC patients. Our findings may be useful for improving patient prognoses and decision-making when providing individualized treatments.

show abstract

“…1b). Recent meta-analysis still considers diffuse sclerosing variant as a high-risk PTC because of a high incidence of extrathyroid invasion at surgery, advanced tumor stage at presentation and bilaterality, however there is an obvious trend in the modern institutional series that diffuse sclerosing variant PTC has no adverse effect on survival [101][102][103][104][105] (Table 2).…”

Section: Diffuse Sclerosing Variant Ptcmentioning

confidence: 99%